76 related articles for article (PubMed ID: 20199587)
1. Deoxyuridine analog nucleotides in deoxycytidine analog treatment: secondary active metabolites?
Jansen RS; Rosing H; Schellens JH; Beijnen JH
Fundam Clin Pharmacol; 2011 Apr; 25(2):172-85. PubMed ID: 20199587
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the effect of phosphorylated metabolites of anti-human immunodeficiency virus and anti-hepatitis B virus pyrimidine analogs on the behavior of human deoxycytidylate deaminase.
Liou JY; Krishnan P; Hsieh CC; Dutschman GE; Cheng YC
Mol Pharmacol; 2003 Jan; 63(1):105-10. PubMed ID: 12488542
[TBL] [Abstract][Full Text] [Related]
3. Phosphorylation of Cytidine, Deoxycytidine, and Their Analog Monophosphates by Human UMP/CMP Kinase Is Differentially Regulated by ATP and Magnesium.
Hsu CH; Liou JY; Dutschman GE; Cheng YC
Mol Pharmacol; 2005 Mar; 67(3):806-14. PubMed ID: 15550676
[TBL] [Abstract][Full Text] [Related]
4. Use of 5-fluorodeoxycytidine and tetrahydrouridine to exploit high levels of deoxycytidylate deaminase in tumors to achieve DNA- and target-directed therapies.
Mekras JA; Boothman DA; Perez LM; Greer S
Cancer Res; 1984 Jun; 44(6):2551-60. PubMed ID: 6539164
[TBL] [Abstract][Full Text] [Related]
5. Kinetic interaction of 5-AZA-2'-deoxycytidine-5'-monophosphate and its 5'-triphosphate with deoxycytidylate deaminase.
Momparler RL; Rossi M; Bouchard J; Vaccaro C; Momparler LF; Bartolucci S
Mol Pharmacol; 1984 May; 25(3):436-40. PubMed ID: 6203026
[TBL] [Abstract][Full Text] [Related]
6. Protective, tumor-selective dual pathway activation of 5-fluoro-2'-deoxycytidine provided by tetrahydrouridine in mice bearing mammary adenocarcinoma-755.
Boothman DA; Briggle TV; Greer S
Cancer Res; 1987 May; 47(9):2344-53. PubMed ID: 2436761
[TBL] [Abstract][Full Text] [Related]
7. Modulation of human UMP/CMP kinase affects activation and cellular sensitivity of deoxycytidine analogs.
Liou JY; Lai HR; Hsu CH; Chang WL; Hsieh MJ; Huang YC; Cheng YC
Biochem Pharmacol; 2010 Feb; 79(3):381-8. PubMed ID: 19765547
[TBL] [Abstract][Full Text] [Related]
8. Use of 5-trifluoromethyldeoxycytidine and tetrahydrouridine to circumvent catabolism and exploit high levels of cytidine deaminase in tumors to achieve DNA- and target-directed therapies.
Mekras JA; Boothman DA; Greer SB
Cancer Res; 1985 Nov; 45(11 Pt 1):5270-80. PubMed ID: 2932216
[TBL] [Abstract][Full Text] [Related]
9. Incorporation of 5-substituted analogs of deoxycytidine into DNA of herpes simplex virus-infected or - transformed cells without deamination to the thymidine analog.
Fox L; Dobersen MJ; Greer S
Antimicrob Agents Chemother; 1983 Mar; 23(3):465-76. PubMed ID: 6303214
[TBL] [Abstract][Full Text] [Related]
10. Modulation of deoxynucleotide metabolism by the deoxycytidylate deaminase inhibitor 3,4,5,6-tetrahydrodeoxyuridine.
Heinemann V; Plunkett W
Biochem Pharmacol; 1989 Nov; 38(22):4115-21. PubMed ID: 2688654
[TBL] [Abstract][Full Text] [Related]
11. Effects of hydroxyurea and thymidine derivatives on the uptake and metabolism of deoxycytidine and arabinofuranosylcytosine in log phase and contact-inhibited human diploid fibroblasts.
Snyder RD; Malick NC
Mol Pharmacol; 1985 Dec; 28(6):574-80. PubMed ID: 4079913
[TBL] [Abstract][Full Text] [Related]
12. Crystal structures of Streptococcus mutans 2'-deoxycytidylate deaminase and its complex with substrate analog and allosteric regulator dCTP x Mg2+.
Hou HF; Liang YH; Li LF; Su XD; Dong YH
J Mol Biol; 2008 Mar; 377(1):220-31. PubMed ID: 18255096
[TBL] [Abstract][Full Text] [Related]
13. Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU).
Beumer JH; Parise RA; Newman EM; Doroshow JH; Synold TW; Lenz HJ; Egorin MJ
Cancer Chemother Pharmacol; 2008 Jul; 62(2):363-8. PubMed ID: 17899082
[TBL] [Abstract][Full Text] [Related]
14. Modulation of deoxycytidylate deaminase in intact human leukemia cells. Action of 2',2'-difluorodeoxycytidine.
Xu YZ; Plunkett W
Biochem Pharmacol; 1992 Nov; 44(9):1819-27. PubMed ID: 1449536
[TBL] [Abstract][Full Text] [Related]
15. Reversal of deamination-related cytotoxicity of 5-methyl-2'-deoxycytidine by tetrahydrouridine in human leukemia cells.
Jekunen A; Vilpo JA
J Natl Cancer Inst; 1984 Nov; 73(5):1087-91. PubMed ID: 6593484
[TBL] [Abstract][Full Text] [Related]
16. 2',3'-Dideoxycytidine: regulation of its metabolism and anti-retroviral potency by natural pyrimidine nucleosides and by inhibitors of pyrimidine nucleotide synthesis.
Balzarini J; Cooney DA; Dalal M; Kang GJ; Cupp JE; DeClercq E; Broder S; Johns DG
Mol Pharmacol; 1987 Dec; 32(6):798-806. PubMed ID: 2826994
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine in mice.
Beumer JH; Eiseman JL; Parise RA; Joseph E; Holleran JL; Covey JM; Egorin MJ
Clin Cancer Res; 2006 Dec; 12(24):7483-91. PubMed ID: 17138702
[TBL] [Abstract][Full Text] [Related]
18. Tumor-selective metabolism of 5-fluoro-2'-deoxycytidine coadministered with tetrahydrouridine compared to 5-fluorouracil in mice bearing Lewis lung carcinoma.
Boothman DA; Briggle TV; Greer S
Cancer Res; 1987 May; 47(9):2354-62. PubMed ID: 2952263
[TBL] [Abstract][Full Text] [Related]
19. Interaction of the high-affinity inhibitor tetrahydro-dUMP with the allosteric enzyme deoxycytidylate aminohydrolase.
Nucci R; Febbraio F; Piccialli G; de Napoli L; Vaccaro C; Rossi M; Whitehead EP
Arch Biochem Biophys; 1994 Apr; 310(1):49-53. PubMed ID: 8161220
[TBL] [Abstract][Full Text] [Related]
20. Human deoxycytidylate deaminase. Substrate and regulator specificities and their chemotherapeutic implications.
Mancini WR; Cheng YC
Mol Pharmacol; 1983 Jan; 23(1):159-64. PubMed ID: 6306421
[No Abstract] [Full Text] [Related]
[Next] [New Search]
